Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay

Cited 24 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorJ C Kim-
dc.contributor.authorD D Kim-
dc.contributor.authorY M Lee-
dc.contributor.authorT W Kim-
dc.contributor.authorD H Cho-
dc.contributor.authorM B Kim-
dc.contributor.authorS G Ro-
dc.contributor.authorSeon-Young Kim-
dc.contributor.authorYong Sung Kim-
dc.contributor.authorJ S Lee-
dc.date.accessioned2017-04-19T09:13:12Z-
dc.date.available2017-04-19T09:13:12Z-
dc.date.issued2009-
dc.identifier.issn0179-1958-
dc.identifier.uri10.1007/s00384-008-0590-1ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/8832-
dc.description.abstractBackground and aims: This study was to evaluate the efficacy of histone deacetylase (HDAC) inhibitors in colorectal cancer together with other established regimens. Materials and methods: Chemosensitivities of 114 colorectal cancer patients to established regimens (fluorouracil (5-FU with leucovorin (FL), capecitabine, FL with irinotecan (FLIRI), and FL with oxaliplatin (FLOX)) as well as five hydroxamic acid derivatives (suberoylanilide hydroxamic acid, PXD101, and three novel candidates of CG-1, CG-2, and CG-3) were comparatively evaluated using the histoculture drug response assay. Results: The chemosensitivity with established regimens was between 34.2% and 52.6%, when the cutoff value of the inhibition ratio was set at 30%, and between 54.5% and 84.1% with HDAC inhibitors. All HDAC inhibitors displayed synergistic effects in combination with established regimens of FLOX and FLIRI (P ≤ 0.0001 - 0.002). Advanced T- and N-category tumors and patients with synchronous adenoma displayed higher chemosensitivity to CG-3, CG-2, and CG-1, respectively, on a multivariate analysis (P = 0.023, 0.044, and 0.045, respectively). Tumors with mismatch repair defects were closely correlated with chemosensitivities to combined regimens of PDX101 with FLOX and FLIRI (P = 0.044 and 0.048, respectively). Conclusions: Our findings firstly demonstrated the chemo-responsiveness of colorectal cancers to HDAC inhibitors with therapeutic efficacy comparable to the established regimens. Additionally, tumor growth and heredity were significantly associated with specific regimens, supporting their possible role as chemosensitive predictors.-
dc.publisherSpringer-
dc.titleEvaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay-
dc.title.alternativeEvaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay-
dc.typeArticle-
dc.citation.titleInternational Journal of Colorectal Disease-
dc.citation.number2-
dc.citation.endPage218-
dc.citation.startPage209-
dc.citation.volume24-
dc.contributor.affiliatedAuthorSeon-Young Kim-
dc.contributor.affiliatedAuthorYong Sung Kim-
dc.contributor.alternativeName김진-
dc.contributor.alternativeName김대-
dc.contributor.alternativeName이유-
dc.contributor.alternativeName김태-
dc.contributor.alternativeName조동-
dc.contributor.alternativeName김문-
dc.contributor.alternativeName노성-
dc.contributor.alternativeName김선영-
dc.contributor.alternativeName김용성-
dc.contributor.alternativeName이중-
dc.identifier.bibliographicCitationInternational Journal of Colorectal Disease, vol. 24, no. 2, pp. 209-218-
dc.identifier.doi10.1007/s00384-008-0590-1-
dc.subject.keywordChemosensitivity-
dc.subject.keywordColorectal adenocarcinomas-
dc.subject.keywordHistoculture drug response assay (HDRA)-
dc.subject.keywordHistone deacetylase inhibitor-
dc.subject.localChemosensitivity-
dc.subject.localchemosensitivity-
dc.subject.localColorectal adenocarcinomas-
dc.subject.localColorectal adenocarcinoma-
dc.subject.localcolorectal adenocarcinomas-
dc.subject.localHistoculture drug response assay-
dc.subject.localHistoculture drug response assay (HDRA)-
dc.subject.localHistone deacetylase inhibitor-
dc.subject.localhistone deacetylase inhibitor-
dc.description.journalClassY-
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.